

---

---

**PRIVILEGED AND CONFIDENTIAL**

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934

May 2018

Commission file number: 001-36288

**Akari Therapeutics, Plc**  
(Translation of registrant's name into English)

75/76 Wimpole Street  
London W1G 9RT  
United Kingdom  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): \_\_\_\_\_

---

---

## CONTENTS

On May 8, 2018, Dr. David Horn Solomon, resigned as Chief Executive Officer and as a member of the Board of Directors (“Board”) of Akari Therapeutics, Plc (the “Company”), effective immediately.

Dr. Horn Solomon’s resignation follows the results of an investigation conducted, with the assistance of an independent law firm, which revealed that Dr. Horn Solomon incurred personal charges on the Company’s corporate credit cards in violation of Company policy. The Company does not consider the amounts charged to be material to the Company’s operations.

Also effective on May 8, 2018, the Board appointed Clive Richardson to serve as the Company’s interim CEO. Mr. Richardson has served on the Company’s Board and as the Company’s COO for over two years. The Company is actively seeking a full-time CEO.

The information contained in this report is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Akari Therapeutics, Plc  
(Registrant)

By: /s/ Clive Richardson  
Name: Clive Richardson  
Interim Chief Executive Officer and Chief  
Operating Officer

Date: May 11, 2018

---